We support and offer a diverse range of services in the areas of recombinant DNA technology, antibody gene sequencing, mutagenesis, library generation, plasmid DNA preparation, microbial genome engineering, gene expression analysis and IVT mRNA synthesis.
Antibody sequence information from hybridoma is essential for protection, preservation and optimization of monoclonal antibodies (mAbs). Antibody gene sequencing and reformatting at Aurigene is a one-stop solution for recombinant expression and production of antibodies;
Experienced in genome scale modification of bacterial and yeast strains for production of recombinant proteins, platform chemicals and metabolic engineering.
Constructing cDNA libraries, phage libraries and yeast libraries along with provisions for high throughput screening and functional characterization.
Regulation and expression of genes at the transcriptional and translational stages play a crucial role in determining gene function. Scientists at APSL carry out routine expression studies by several methods;
Residual host-cell proteins (HCP) and host-cell DNA (HCD) are impurities that remain in a recombinant biotherapeutics. We ensures that these impurities and contaminants are detected and reduced to levels below those guided by regulatory agencies.
The state-of-the-art laboratory equipped with high-end instrumentation supported by experienced IT and engineering teams, at Aurigene supports discovery and development services under biology capabilities.
Aurigene Pharmaceutical Services is
that provides contract research and manufacturing services
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.